Shannon Heaning, Content Associate

Imsidolimab gained EU orphan designation for GPP as the IL-36 receptor inhibitor advances toward a December 2026 FDA decision.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Victoria Garcia-Albea, NP, discussed the learning curve for dermatology NP fellows and how continued education parallels the evolution of the specialty.

Eileen Cheever, PA, shared how mentorship, experienced colleagues, and conference attendance can support professional growth and patient care.

A practical guide to baseline testing, follow-up laboratory monitoring, and managing abnormalities in patients receiving oral JAK inhibitors.

Stay ahead with a weekly roundup of the biggest practice management, AI, policy, business, and professional development updates in dermatology.

Stephanie Kauffman, CEO of the Melanoma Research Alliance, discussed the organization's research priorities as it approaches 20 years of advancing melanoma research.

Goran Mićević, MD, PhD, joined Christopher Bunick, MD, PhD, to discuss phase 3 findings showing an individualized mRNA neoantigen therapy improved outcomes with checkpoint blockade in resected melanoma.

MotherToBaby launched a pregnancy study to address limited safety data for lebrikizumab use in patients with atopic dermatitis.

Preclinical data show GX-03 reduced IL-31 by nearly 68% and dermatitis severity by 66% in a murine model of atopic dermatitis.

Joan Levy, PhD, chief science officer at the Melanoma Research Alliance, discussed the significance of Tudriqev's accelerated approval for patients with anti-PD-1-refractory melanoma.

Jennifer Song, MD, discussed icotrokinra, expanding pediatric psoriasis options, emerging TYK2 inhibitors, and GLP-1 combination data.

Daniel Butler, MD, discussed how aging affects psoriasis presentation and the insurance challenges facing older patients in a recent Dermatology Times interview.

Judson Brewer, MD, PhD, discussed how the trigger-behavior-result habit loop model can be applied to itch-scratch cycles in atopic dermatitis.

LEO Pharma will acquire worldwide rights to dersimelagon, an investigational oral therapy under FDA review for EPP and XLP.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Updated Allergan Partner Privileges offers simplified savings, greater benefits transparency, portfolio-level rewards, and a new BOTOX Cosmetic growth rebate.

Chantel K. Hillestad, MSN, DCNP, FNP-C, discusses recurrent MCC, treatment access, and care coordination for patients in rural communities.

Review common questions about psoriasis, including systemic disease, PsA screening, treatment selection, triggers, and patient counseling.

Long-term envudeucitinib data showed increasing skin clearance through 48 weeks, with 54% of continuously treated patients achieving PASI 100.

Oyetewa Asemba, MD, discussed common mistakes in hair loss and pigmentary disorder care, from scalp exams to treatment vehicle selection.

Eileen Cheever, PA, discussed family hesitancy toward systemic pediatric psoriasis treatment and age-related treatment gaps in dermatology.

Test your knowledge of GPP recognition, clinical presentation, complications, and targeted treatment!

Victoria Garcia-Albea, NP, discussed the learning curve dermatology NP fellows experience and the need for greater dermatology education for APPs.

An MCC case illustrates how travel distance and limited oncology access can influence treatment decisions and adherence in rural patients.

Aaron Farberg, MD, discusses Isoclear’s 3-phase approach to acne treatment, from active breakouts to long-term skin maintenance.

Lisa Swanson, MD, FAAD, discussed expanding oral JAK inhibitor options for younger children with atopic dermatitis and alopecia areata.

Envudeucitinib achieved PASI 100 in 54% of continuously treated patients at 48 weeks in the phase 3 ONWARD3 extension study.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Eileen Cheever, PA, discussed how understanding immunologic pathways can strengthen patient counseling and treatment confidence in dermatology.